Background {#Sec1}
==========

Labeling of medicines is a legislative requirement for conveying information about medicines to patients. It provides information on brand, type of drug enclosed within the packaging, strength and quantity of product, appropriate users, instructions, indications, contraindications and side-effects \[[@CR1]\]. Therefore, appropriate labeling of medicines is crucial for ensuring patient medication safety, while its ambiguity is associated with administration errors due to incorrect interpretations of products \[[@CR2]\]. It has been suggested that medication compliance, distinction, and their readability are affected by medicine labeling that includes design features such as signal word, color, format, wording, language etc. \[[@CR3]\]. Evidences demonstrate that marketed pharmaceutical products have, at times, failed to meet the standard labeling requirements \[[@CR4], [@CR5]\]. Moreover, studies have also claimed that dispensed pharmaceutical medicines lacked the prescribed labeling requirements \[[@CR6], [@CR7]\]. As there are inadequacies in identification and reporting of such requirements in Nepal, Department of Drug Administration (DDA), which is the national medicine regulatory authority, should be more vigilant on such issues \[[@CR8]--[@CR10]\]. In Nepal, allopathic drugs are classified as "a", "b", or "c", with respective sub-categories. Category "a" consists narcotic and poisonous drugs; category "b" consists antibiotics, hormones etc. that require a prescription for dispensing from pharmacies; and category "c" usually consists over-the-counter (OTC) drugs. It has been made obligatory by DDA for pharmaceutical companies to properly label their pharmaceutical products according to the provisions mentioned in Drug Standard Regulation, 2043 (1986 AD) of Nepal \[[@CR11]\]. At times, inabilities to follow foreign-language labeling of OTC drugs have resulted in adverse outcomes \[[@CR12]\]. To overcome this, DDA has mandated to mention at least name of the drug, directions of use, category/caution, price of the drug, date of production, batch number and expiry date of twenty category "c" medicines in Nepali language \[[@CR13]\]. Still then, Nepalese pharmaceutical industries are striving harder to meet the regulatory requirements \[[@CR14]\]. It has also been reported that the same generic medicine is placed in two different categories by different pharmaceutical industries \[[@CR14]\]. However, the data on this issue is rare in literatures. Therefore, we aimed to assess the primary labeling of medicines manufactured and marketed by Nepalese pharmaceutical industries.

Methods {#Sec2}
=======

Primary labeling of medicines manufactured by Nepalese pharmaceutical industries was assessed between November to December 2017. Only the medicines available at CMCTH, a tertiary hospital located in Chitwan district, Nepal, was assessed. CMCTH was purposefully selected because its pharmacy dispenses most products manufactured by Nepalese Pharmaceutical industries. This hospital only practices allopathic medicines; hence this study only included such medicines. The primary labeling of marketed medicines was assessed as required by Drug Standard Regulation, 2043 (1986 AD) of Nepal \[[@CR11]\]. The regulation states that the marketed medicines for human use should contain 16-points information in primary labeling that includes Drug name and quantity; Category and sub category of the drug; System of medicine; Name of active ingredient, quantity and the pharmacopoeia; Name of the drug production company, address and the country; Serial number for the establishment of drug industry; Serial number for the production of the drug; Batch number; Date of production; Date of expiry; Price; Storing methods (techniques) and management of the drug; Caution in Group "a" and "b" (may not be sold without the prescription of a registered medical practitioner); Quantity; Method of use; and additional information on External preparation (only for external use). The primary labeling should contain at least the name of the drug, method of use, category/caution, price, date of production, batch number, and date of expiry of 20 category "c" drugs in Nepali language \[[@CR13]\]. A checklist was developed to assess these aforementioned requirements of primary labeling of all kinds of dosage forms. A market basket method (total collection of all available branded generic medicines) was used for sample collection. The appropriateness of classification was also assessed according to Drug Standard Regulation, 2043 (1986 AD) \[[@CR11]\]. Descriptive statistics was performed using IBM SPSS version 20 (IBM Corporation, Armonk, NY, USA). The collected generic medicines were categoried according to therapeutic categories and expressed as frequency and percentage.

Results {#Sec3}
=======

This study assessed primary labeling of 759 medicines manufactured by 37 Nepalese pharmaceutical industries. The types of dosage forms assessed are depicted in Table [1](#Tab1){ref-type="table"}.Table 1Type of dosage form assessed (*n* = 759)\*Dosage formn(%)Tablet and Capsule617(81.3)Oral Solution, Syrup, Suspension and Drop65(8.6)Ointment, Cream and Gel40(5.3)Injection21(2.8)Nasal Drop5(0.7)Eye and Ear Drop4(0.5)Mouth Gargle3(0.4)External solution and lotion3(0.4)Powder1(0.1)\*Percentage do not add up to 100 due to single decimal place

Of 759 medicines, majority belongs to antimicrobial drugs (20.2%), followed by antihypertensive drugs (13.6%) and vitamins and minerals (8.5%). Details about the therapeutic categories of drugs assessed during study were illustrated in Table [2](#Tab2){ref-type="table"}.Table 2Classification of drugs based on therapeutic categories (*n* = 759)Therapeutic Categories of Drugsn(%)Antidepressants35(4.6)Antidiabetics58(7.6)Antihypertensives103(13.6)Antimicrobials153(20.2)Lipid- lowering Drugs23(3.0)Hypnotics and sedatives18(2.4)Antipsychotics15(2.0)Corticosteroids16(2.1)Vitamins and minerals65(8.5)Anti-cold and Cough preparations13(1.7)Anticoagulants5(0.7)Analgesic, Anti-inflammatory Drugs and Antipyretics55(7.2)Antiepileptics12(1.6)H~1~-antihistamines32(4.2)Proton-pump inhibitors27(3.6)Antiemetics9(1.2)Antispasmodics15(2.0)Bronchodilators and Anti-asthma Drugs14(1.8)Muscle relaxants14(1.8)Antigout Drugs7(0.9)Tropical Nasal Decongestants5(0.7)Miscellaneous65(8.6)

Primary labeling of all pharmaceutical products had the name of the drug (brand); however, only over three-quarters of products had stated the quantity of the drug. Similarly, almost all the products declared the category of the drug while only a few products (4.1%) mentioned the sub-category. The system of medicines was stated in around one out of 10 products. Active ingredients and their quantity were mentioned in almost all products. But, 11% products lacked the name of pharmacopoeia belonging to the drug. None of the products mentioned serial number for establishment of pharmaceutical industry. Almost all products stated drug production company, address and country, serial number for production of drug, date of production, storing methods \[but keep out of reach of children was not mentioned in 46(6%) products\] and information on quantity used. Similarly, all products had the batch number and the date of expiry. However, five out of 100 products did not list their selling price. Few Group "a" and Group "b" products (2.4%) lacked caution labeling (not to be sold without the prescription of a registered medical practitioner). More importantly, approximately seven percentage of products were found to provide misleading information with respect to caution \[example: stating 'not to be sold without the prescription of a registered medical practitioner' in case of OTC drugs (Group "c")\]. Unfortunately, majority of products (84.4%) did not provide information on directions of use. The appropriate drug classification was found in 89.6% of products (Table [3](#Tab3){ref-type="table"}).Table 3Information mentioned in primary labeling of medicines (*n* = 759)InformationCategoriesn(%)Drug name (Brand)Yes759(100)Drug quantityYes583(76.8)Category of drugYes757(99.7)Sub-category of drugYes31(4.1)System of medicineYes75(9.9)Active ingredient and quantityYes758(99.9)PharmacopoeiaYes676(89.1)Drug production company, address and countryYes758(99.9)Serial number for establishmentYes0(0)Serial number for productionYes757(99.7)Batch numberYes759(100)Date of productionYes752(99.1)Date of expiryYes759(100)PriceYes719(94.7)StorageYes759(99.9)\*Caution in Group "a" and "b" (not to be sold without the prescription of a register medical practitioner)Yes588(77.5)No18(2.4)Misleading information52(6.9)Not applicable (Category c)101(13.3)Quantity to be usedYes743(97.9)Method of useYes116(15.3)External preparation (only for external use) (*n* = 55)Yes54(98.2)Appropriateness of drug categoryAppropriate680(89.6)Inappropriate77(10.1)Unable to assess2(0.3)\*Percentage do not add up to 100 due to single decimal

Out of 88 OTC products studied, almost all mentioned the drug name and category of drug in Nepali language as provisioned in the DDA's requirements. As shown in Table [4](#Tab4){ref-type="table"}, some information were not assessed because they were lacking. While a total of 18.2% OTC products stated directions of use, only 14.8% of products mentioned it in Nepali language. Most of the OTC products (84.1%) mentioned only necessary precautions in Nepali language, but majority of them were found without batch number (84.1%), date of production (83%), date of expiry (84.1%) and price (76.1%) in Nepali language (Table [4](#Tab4){ref-type="table"}).Table 4Assessments of labeling of OTC (DDA listed) medicines where certain information required to write in Nepali language (*n* = 88)InformationCategoriesn(%)Drug name (brand) in Nepali languageYes87 (98.9)Method of use in Nepali languageYes13(14.8)No3(3.4)Unable to assess69(78.4)Category of drug in Nepali languageYes85(96.6)Precaution taken in Nepali languageYes74(84.1)No13(14.8)Unable to assess1(1.1)\*Price Nepali languageYes15(17.0)No67(76.1)Unable to assess6(6.8)Date of production in Nepali languageYes14(15.9)No73(83)Unable to assess1(1.1)Date of expiry in Nepali languageYes14(15.9)Batch number in Nepali languageYes14(15.9)\*Percentage do not add up to 100 due to single decimal

Other labeling errors were also encountered during the assessment of primary labeling. This included duplication of same information in two products (0.3%), while sticker with new price by erasing original price, inappropriate dosage information, incorrect method of use, no printed information (except batch number, date of production, date of expiry and price), erasing of drug category with permanent marker, each of which were observed in different single product (0.1%).

Discussion {#Sec4}
==========

The pharmaceutical sector of Nepal continues to grow, with over 15,000 registered products, over 300 registered manufacturing facilities and over 16,000 pharmacy outlets. This growth demands additional human resources for the regulatory authority (DDA) to improve regulation and smooth functioning of the authority body \[[@CR15]\]. As a consequence, the gap between regulatory provision and actual practice has been documented. \[[@CR8]--[@CR10]\]. To keep this in check, primary labeling of medicines should be assessed on a regular basis.

Studies have demonstrated that labeling and packaging are causal factors for medication errors \[[@CR2], [@CR16]--[@CR18]\]. Therefore, appropriate labeling of marketed medicines is necessary for fulfilling the regulatory provision and ensuring patient medication safety \[[@CR3]\]. As observed in this study, nearly a quarter of products were lacking information on quantity or strength of the drug. This might be due to difficulty in stating strength along with their brand name in those products containing multiple active ingredients. However, it was observed that almost all products had information on active ingredient(s) and respective quantity to communicate the composition of products. Majority of products had not mentioned sub-category of drugs on their labeling but mandatory presence of this information from the perspective of consumers still remains controversial. Similarly, most of the products were found to lack information on system of medicine they belong to. Practice of categorizing drugs as "a", "b" or "c" was observed. Pharmacopoeial standard of product, which essentially reflects standard of the product, \[[@CR19]\] was missing in some of the labels. Perhaps, this issue should be of serious concern for stakeholders because this is considered important for drug safety and is of special concern for consumers. Drug Standard Regulation, 2043 (1986 AD) mentions that products need to have serial number for establishment of pharmaceutical industries \[[@CR11]\]. This provision was found ignored on labelling of all medicines of all drug companies that were assessed. This might be because it is considered less relevant to patients and healthcare professionals. In this study, all products were observed to include storage information, except for 6% of them that did not have information regarding "keep out of reach of children". Study in Nigeria reported 89.6% pharmaceutical products had adequate storage instructions \[[@CR5]\]. However, this study also included products other than requiring prescription (OTC, antiseptics, disinfectants, detergents, household items, insecticides and consumables). Similarly, majority of medicines stated caution (not be sold without the prescription of a registered medical practitioner) (77.5%) and quantity to be used (97.9%) in this study. Printed words were not always in red or orange, and some products were found to lack 'signal words' (e.g. caution, warning) in this study. Printing of such words in colors other than red or orange have been known to lower the perceived hazard and higher proportion of compliant behavior, with red conveying it the strongest \[[@CR20]\]. Similarly, it has been demonstrated that the presence of a 'signal word' increases perceived product hazard compared to its absence \[[@CR21]\]. During this study, we also observed caution mentioned in group 'c' drugs, which might be misleading. In Nigeria, a lower proportion of pharmaceutical products adequately mentioned warning and dosage instruction on the labeling of pharmaceutical products \[[@CR5]\] but we argue that in Nepal products such as household items, insecticides, detergents and consumables do not come under Drug Act, which was included by this study. However, this study has performed a detail investigation on warning including exploration of first aid instructions as well as sign and symptoms of product toxicity and their treatment. Most of the products in this study had no directions of use, which is important to avoid medication errors \[[@CR22]\], especially for modified-release products. For instance, labeling "swallow tablet as a whole without breaking or cursing" on controlled released tablets and "tablets should be chewed before swallowing" on chewable tablets are needed to ensure that patients use it in the intended manner. Studies in SriLanka \[[@CR6]\] and Malaysia \[[@CR7]\] have also reported insufficient labeling of dispensed medicines as required by the regulatory authorities. The study done in SriLanka used WHO manual for household survey, and included both Western and traditional medicine but did not evaluate repackaging by family members and their understanding of medication administration instruction \[[@CR6]\]. Similarly, study in Malaysia used simulated client method to explore labeling requirement of dispensed medicine using a case of common cold but limits itself to single simulated case, observer bias and being a pilot study \[[@CR7]\]. Therefore, improved assessment and monitoring of primary labeling of marketed medicines is a dire need.

Medication labeling is rarely available in languages other than English, placing patients with limited English proficiency at greater risk of misunderstanding medication instructions and warnings \[[@CR23]--[@CR26]\]. To overcome this, DDA has necessitated to write at least name of the drug, method of use, category/caution, price, date of production, batch number and date of expiry of 20 category "c" drugs in Nepali language. However, this study demonstrated that none of the products under study totally adhered to this requirement. Besides this, the print size of label was also very small to read. Studies have shown an association between the print sizes and medication errors \[[@CR27], [@CR28]\]. This might contribute to increased medication errors particularly by the elderly people. Therefore, pharmaceutical industries should consider the use of medium and large print to increase readability \[[@CR28]\], at least for OTC medicines. Other alternative may be to include comprehensive, clear drug leaflets in individual packs of OTC medicines as they are frequently self-administered without consultation with healthcare professionals. Moreover, confusion between look-alike products can be reduced by using Tall man (capital) letters to write drug names \[[@CR29]\]. In this study, labeling errors such as the use of sticker with new price to cover the original price, duplication of same information, and so on were also observed. Different countries have their own regulatory provisions for labeling of pharmaceuticals products, because of which, it was not completely compatible with labeling requirement of other countries \[[@CR4]\]. Therefore, foreign manufacturers should also comply with labeling requirements before registration of their product in the country of their interest.

Issues on such labeling errors should be removed through strict assessment of medicine labeling by the DDA and also by stakeholders (Manufacturers, Importers and pharmacy outlets). To overcome this, DDA has implemented Drug administration and management system (DAMS) software and warranted all manufacturers to put detailed information of the products in the software before registration/renewal of their products. Additionally, some sort of hologram, for example, as issued by regulatory authority itself, can also be conceptualized to remove counterfeits related to labels.

This study is the first of its kind in Nepal that assessed the scenario of primary labeling inadequacy and suggests stakeholders to rectify them. This is also useful to identify counterfeit and falsified medicines from true ones, which is an overwhelming problem in Nepal. However, this study has certain limitations that should be taken into account while approaching its findings. Limited number of products from only one system of medicine and from single pharmacy outlet were assessed. Also, this study does not cover factors influencing primary labeling of medicine manufactured by Nepalese pharmaceutical industries.

The results of this study highlight the need for stringency in assessment and evaluation of labels of medicines prior to their approval. Further, the regulatory authority need to closely inspect those approved labels for compliance to the provisions during periodic inspections. The Nepalese pharmaceutical industries should also improve their labeling standards/requirements as a part of GMP compliance. Therefore, all stakeholders should take into consideration that improving labeling requirements will eventually improve patients' safety, products' quality and provides thorough information like usage and storage requirements.

Conclusions {#Sec5}
===========

The present study demonstrates a gap between regulatory provisions for primary labeling of Nepalese pharmaceutical products and their actual labeling in medicines. It highlights the need for continued monitoring, reassessment and improvement of labeling of pharmaceutical products manufactured by Nepalese pharmaceutical industries.
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